45 results
8-K
EX-99.1
GRTX
Galera Therapeutics Inc
11 May 23
Galera Reports First Quarter 2023 Financial Results and Recent Corporate
7:11am
of historical data in the literature. Based on these data, Galera intends to pursue a strategy for avasopasem, if approved for the reduction of SOM … , strategy development, and execution in preparation for the potential U.S. commercial launch of avasopasem in 2023.
First Quarter 2023 Financial Highlights
8-K
EX-99.1
GRTX
Galera Therapeutics Inc
28 Apr 21
Regulation FD Disclosure
12:00am
statements regarding future results of operations and financial position, business strategy, the safety, efficacy, regulatory and clinical progress … , including statements regarding future results of operations and financial position, business strategy, the safety, efficacy, regulatory and clinical
8-K
EX-99.1
GRTX
Galera Therapeutics Inc
8 Sep 21
Regulation FD Disclosure
7:09am
of operations and financial position, business strategy, the safety, efficacy, regulatory and clinical progress, and therapeutic potential of current … strategy intended to optimize patient access Head and neck cancer not a focus for cost control measure Favorable Payer Landscape
Beyond Oral Mucositis
10-Q
2019 Q3
GRTX
Galera Therapeutics Inc
10 Dec 19
Quarterly report
7:31am
and manufacturing capabilities and strategy, our expectations about the willingness of healthcare professionals to use our product candidates, the sufficiency … in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our
8-K
EX-99.1
GRTX
Galera Therapeutics Inc
16 May 22
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
7:36am
on its development strategy to advance its lead program, avasopasem, toward potential commercialization. To that end, we are delighted to attend
8-K
EX-99.2
tnw8zk9b0 rjn712
14 Dec 21
Galera Announces Primary Endpoint Met Statistical Significance in Corrected
7:06am
DRS/A
l8n98p9t388qdvpx6x
23 Apr 19
Draft registration statement (amended)
12:00am
DRS/A
jugt5d8nfyjyro 19m8
9 Aug 19
Draft registration statement (amended)
12:00am
DRS
6nn6z5lz1tb 678yadkl
15 Mar 19
Draft registration statement
12:00am
10-K
e7oybm3 3f
10 Mar 20
Annual report
7:36am
S-1
vetql67rtxg
11 Oct 19
IPO registration
5:27pm
424B4
sbx3mfpv2 kkqwvck
8 Nov 19
Prospectus supplement with pricing info
4:41pm
S-1/A
dzknb
28 Oct 19
IPO registration (amended)
7:16am
DRS/A
j07y1rmngq7zpinev6
12 Sep 19
Draft registration statement (amended)
12:00am